Under a tenth of people that would benefit from weight-loss injections such as Wegovy can access them, warns the WHO as it publishes its inaugural recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a chronic disease that can be treated with thorough and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant obstacles to broad availability to the injections that can help people shift significant body mass, says the agency.
Skinny Jab Supply Crisis
Despite the present most optimistic case, the manufacturing of GLP-1 therapies could only cover around 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation encourages nations and manufacturers to widen access, through approaches like patent sharing.
Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.
How Obesity Jabs Operate
These medications mimick a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so users consume fewer calories.
Individuals commonly start to lose weight in the initial weeks of beginning the weekly injections.
Research suggests people may put most of the weight back on after a year of discontinuing the drug, when their normal hunger return.
To be overweight or obese raises your risk for developing diseases, such as diabetes, heart disease, stroke, and specific cancers.
Excess weight concerns individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
